Proresolving lipid mediators and diabetic wound healing

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 2, 2012, Pages 104-108

  Hellmann, Jason ^a   Tang, Yunan ^a   Spite, Matthew ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

inflammation; macrophages; obesity; resolution; resolvins

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXIN A; OMEGA 3 FATTY ACID; PEPTIDOLEUKOTRIENE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BIOSYNTHESIS; BLOOD VESSEL PERMEABILITY; CELL INTERACTION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; LIQUID CHROMATOGRAPHY; MACROPHAGE; MACROPHAGE FUNCTION; MASS SPECTROMETRY; MEDIATOR; METABOLISM; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHAGOCYTOSIS; PHENOTYPIC PLASTICITY; REVIEW; RISK ASSESSMENT; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EICOSANOIDS; FEMALE; HUMANS; INFLAMMATION; LEUKOTRIENES; MACROPHAGES; MALE; PROSTAGLANDINS; ULCER; WOUND HEALING;

EID: 84858183150     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283514e00     Document Type: Review

References (35)

1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361:1545-1551. (Pubitemid 36566350)
2. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140:871-882.
3. Serhan CN. Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25:101-137. (Pubitemid 46697904)
4. Li S, Sun Y, Liang CP, et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 2009; 105:1072-1082.
5. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32:593-604.
6. Brancato SK, Albina JE. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol 2011; 178:19-25.
7. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 2010; 207:1807-1817.
8. Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 2010; 5:e9539. This article establishes that defective macrophage-mediated clearance of apoptotic cells is causally related to delayed wound healing in obese-diabetic mice.
9. Maree AF, Komba M, Finegood DT, Edelstein-Keshet L. A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. J Appl Physiol 2008; 104:157-169.
10. Liu BF, Miyata S, Kojima H, et al. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999; 48:2074-2082. (Pubitemid 29458374)
11. Abrass CK, Hori M. Alterations in Fc receptor function of macrophages from streptozotocin-induced diabetic rats. J Immunol 1984; 133:1307-1312. (Pubitemid 14060082)
12. Mirza R, Koh TJ. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine 2011; 56:256-264. This study documents that classically activated macrophages contribute to delayed wound healing in diabetes.
13. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11:738-739. This excellent review article highlights the association between distinct macrophage subsets in the development of metabolic alterations in obesity.
14. Serhan CN, Brain SD, Buckley, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21:325-332. (Pubitemid 46213480)
15. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-1176. (Pubitemid 17131222)
16. Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 2010; 33:266-278.
17. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986-1000.
18. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107:1170-1184. This review article provides a comprehensive overview of resolvin biosynthesis and the endogenous role of resolvins in regulating the resolution of inflammation.
19. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192:1197-1204.
20. Serhan CN, Hong S, Gronert, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196:1025-1037. (Pubitemid 35231761)
21. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3:279-312. (Pubitemid 351488283)
22. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206:15-23.
23. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447:869-874. (Pubitemid 46920139)
24. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461:1287-1291.
25. Schif-Zuck S, Gross N, Assi S, et al. Saturated-efferocytosis generates proresolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol 2011; 41:366-379.
26. Oh SF, Pillai PS, Recchiuti A, et al. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 2011; 121:569-581. This study elucidates a novel E-series resolvin biosynthetic pathway and highlights the role of E-series resolvins in regulating bacterial killing by phagocytes.
27. Palmer CD, Mancuso CJ, Weiss JP, et al. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol 2011; 90:459-470. Results of this study demonstrate the mechanistic basis whereby D-series resolvins control bacterial killing by phagocytes.
28. White PJ, Arita M, Taguchi R, et al. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010; 59:3066-3073. This is the first study to demonstrate that endogenous levels of omega-3 fatty acids are depleted in insulin-sensitive tissues in obesity and that transgenic restoration of omega-3 fatty acid levels is protective in the context of metabolic disease and is associated with the production of proresolving lipid mediators.
29. Gonzalez-Periz A, Horrillo R, Ferre N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23:1946-1957.
30. Hellmann J, Tang Y, Kosuri M, et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 2011; 25:2399-2407. This is the first study to demonstrate a direct role of D-series resolvins in improving adipose tissue macrophage-mediated inflammation and hyperglycemia in obesity.
31. Spite M. Resolvin D1 promotes resolution of acute inflammation and improves metabolic parameters in obese diabetic mice. Arterioscler Thromb Vasc Biol [abstract] P151. ATVB 2011 Scientific Sessions. http://my.americanheart. org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm-428274.pdf. Results of this study document that D-series resolvins restore defective macrophage phagocytosis in diabetes.
32. Lu Y, Tian H, Hong S. Novel 14,21-dihydroxy-docosahexaenoic acids: structures, formation pathways, and enhancement of wound healing. J Lipid Res 2010; 51:923-932. This is the first study to document that a novel DHA-derived proresolving lipid mediator, 14S, 21R-diHDHA, plays a critical role in normal wound healing.
33. Tian H, Lu Y, Shah SP, Hong S. 14S,21R-dihydroxydocosahexaenoic acid remedies impaired healing and mesenchymal stem cell functions in diabetic wounds. J Biol Chem 2011; 286:4443-4453. This study highlights that a DHA-derived proresolving lipid mediator enhances angiogenesis in diabetic wounds.
34. Tian H, Lu Y, Shah SP, Hong S. Autacoid 14S,21R-dihydroxy-docosahexaenoic acid counteracts diabetic impairment of macrophage prohealing functions. Am J Pathol 2011; 179:1780-1791. This study demonstrates that altered biosynthesis of a proresolving lipid mediator in part underlies defective macrophage-mediated wound healing in diabetes.
35. Norling LV, Spite M, Yang R, et al. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 2011; 186:5543-5547. Results of this study demonstrate that novel nanoparticle-based delivery systems for resolvins enhance keratinocyte wound healing.